European regulators’ human medicines committee recommended approval of Moderna’s mCombriax (mRNA‑1083), a combined influenza and COVID‑19 vaccine for people 50 and older. The CHMP concluded the shot generated adequate antibody responses against both viruses; the recommendation now moves to the European Commission for final authorization. The positive EU decision contrasts with Moderna’s rocky regulatory track in the U.S., where the FDA requested additional flu data and delayed review. Moderna CEO Stéphane Bancel framed the CHMP backing as a milestone for respiratory virus vaccination and for the company’s mRNA vaccine strategy.